P3 Health Partners (NASDAQ:PIII) Posts Earnings Results, Beats Expectations By $5.17 EPS

P3 Health Partners (NASDAQ:PIII) released its earnings results on Thursday. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.85) by $5.17, FiscalAI reports. The firm had revenue of $386.39 million for the quarter, compared to analysts’ expectations of $391.45 million. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%.

Here are the key takeaways from P3 Health Partners’ conference call:

• P3 reported $26 million of adjusted EBITDA in Q1, well above internal expectations, and raised its full-year 2026 outlook to $20 million-$60 million as execution improved.
• The company said its Medicare Advantage medical cost trend was roughly flat versus the full-year 2025 baseline, which it framed as a meaningful differentiator versus peers guiding to 7%+ trend.
• Management highlighted stronger payer economics, including about a 15% year-over-year improvement in MA funding rates and delegated functions covering 63% of membership in 2026.
• The company said its balance sheet improved after roughly $250 million of debt was converted to preferred equity, and it believes it now exceeds the Nasdaq minimum stockholders’ equity requirement.
• Membership declined year over year to about 106,000 at-risk lives as P3 exited lower-economics arrangements, but total lives under management reached about 135,000 including service arrangements and a new Nebraska partnership.

P3 Health Partners Trading Up 180.1%

Shares of PIII stock traded up $7.26 during trading on Friday, reaching $11.29. 65,159,971 shares of the company’s stock traded hands, compared to its average volume of 134,546. The company has a market capitalization of $81.43 million, a P/E ratio of -0.29 and a beta of 0.48. The firm’s 50-day moving average is $3.05 and its 200 day moving average is $3.85. P3 Health Partners has a 1 year low of $1.52 and a 1 year high of $14.35.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PIII. Lake Street Capital reiterated a “buy” rating and issued a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research note on Friday. UBS Group set a $14.00 target price on shares of P3 Health Partners in a research note on Friday. TD Cowen dropped their target price on shares of P3 Health Partners from $8.00 to $3.00 and set a “hold” rating on the stock in a research note on Thursday, April 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of P3 Health Partners in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.33.

P3 Health Partners News Summary

Here are the key news stories impacting P3 Health Partners this week:

• Positive Sentiment: P3 Health Partners reported Q1 2026 earnings of $0.32 per share, beating expectations for a large loss, which appears to be the main catalyst behind the stock’s surge. P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here’s Why
• Positive Sentiment: The company’s revenue for the quarter was $386.39 million, roughly in line with estimates, helping support investor confidence that operating results were better than expected overall. P3 Health Partners earnings press release
• Neutral Sentiment: Trading in PIII was halted several times for LULD pauses, indicating extreme volatility and a fast-moving price reaction to the earnings news.
• Neutral Sentiment: Commentary following the report highlighted that the stock was reacting to a narrower-than-expected loss and a sharp after-hours move, underscoring speculation and momentum trading rather than a fresh business announcement. P3 Health Partners (PIII) stock surges over 42% after hours: Here’s why
• Negative Sentiment: Despite the earnings beat, P3 Health Partners still reported a negative net margin and negative return on equity, so the underlying turnaround story remains unproven.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.